Based on our results demonstrating the role of oxidative metabolism in the regulation of MT1G, it is tempting to speculate that this patient heterogeneity might at least partially reflect individual differences in the effects of sorafenib on the oxidative metabolism of cancer cells in different tumours. This evidence concerns the gene MT1G and cancer.